Education
About Us
Working with TipRanks
Follow Us
SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
1.01Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 11, 2025
|% Change Since: -4.82%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
SIGA had a year of strong financial performance and strategic progress, with notable sales growth and international expansion. Challenges with mpox clinical trials were addressed, but they did not significantly dampen the overall positive trajectory. The company's strong cash position and strategic partnerships provide a solid foundation for future growth.Company Guidance
During the SIGA business update call for the fiscal year 2024, CEO Diem Nguyen highlighted a year of strong financial performance with product sales reaching $133 million, marking a 2% increase from 2023. The fourth quarter alone contributed $80 million to these sales, predominantly from deliveries of oral and IV TPOXX to the U.S. strategic national stockpile and the Department of Defense, as well as an $11 million sale in East Asia. The company reported a pretax operating income of $57 million for the fourth quarter and $70 million for the full year, with net income at $46 million and $59 million, respectively. The diluted earnings per share were $0.63 for the fourth quarter and $0.82 for the full year. SIGA maintained a robust cash position with $155 million in cash and no debt at year-end, and a $70 million outstanding order balance expected to be delivered in 2025. The company also advanced its international presence with a regulatory approval in Japan and assumed responsibility for promoting TPOXX outside the U.S., while continuing to explore strategic partnerships and pipeline diversification, including a collaboration on monoclonal antibodies with Vanderbilt University.Continued Product Sales Growth
2024 product sales reached $133 million, a 2% increase from 2023, marking the second consecutive year of growth.
Significant Fourth Quarter Revenue
$80 million generated in the fourth quarter, driven by diverse revenue sources including the U.S. strategic national stockpile and international markets.
International Expansion Achievements
TPOXX received regulatory approval in Japan, and a notable $11 million sale in East Asia, more than doubling the largest prior sale in the region.
Strong Financial Position
SIGA ended the year with a cash balance of $155 million and no debt, reflecting strong financial discipline.
Strategic Partnerships for Long-term Growth
An exclusive license agreement with Vanderbilt University for monoclonal antibodies with potential to complement the TPOXX franchise.
---
SIGA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SIGA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 11, 2025 | $5.60 | $5.99 | +6.96% |
| Nov 07, 2024 | $7.63 | $7.57 | -0.79% |
| Aug 01, 2024 | $9.24 | $8.70 | -5.84% |
| May 07, 2024 | $10.46 | $7.50 | -28.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does SIGA Technologies Inc (SIGA) report earnings?
SIGA Technologies Inc (SIGA) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is SIGA Technologies Inc (SIGA) earnings time?
SIGA Technologies Inc (SIGA) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SIGA EPS forecast?
Currently, no data Available
---